ReviewPsychedelic medicine (New Rochelle, N.Y.)2024
Getting in Touch with Touch: The Importance of Studying Touch in MDMA-Assisted Therapy and the Development of a New Self-Report Measure.
Review in Psychedelic medicine (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Methodological fragmentation and integration priorities in psychedelic-assisted therapy assessment: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy.Brain and behavior · 2026Trial
- Synergies in psychedelic-assisted therapy: a qualitative interview study of psychotherapeutic processes.Frontiers in psychiatry · 2026Article
- Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.Therapeutic advances in psychopharmacology · 2026Article
- Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.Frontiers in psychiatry · 2025Article
- Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial.Therapeutic advances in psychopharmacology · 2025Article
- The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.Therapeutic advances in psychopharmacology · 2025Article
- Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation.European journal of psychotraumatology · 2024Article
- MDMA modulates human sensorimotor cortical pathways during gentle touch.Imaging neuroscience (Cambridge, Mass.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: MDMA-assisted therapy (MDMA-AT) is an emerging treatment modality, with recent phase 3 trials indicating its potential for regulatory approval. Central to this therapy is the role of touch, yet its empirical evaluation in MDMA-AT, and psychotherapy in general, remains limited. The use of touch in combination with MDMA raises concerns about power imbalances and ethical boundaries. Methods: This article reviews existing literature on therapeutic touch and introduces the Touch Outcomes Measurement Inventory (TOMI). The TOMI is developed to assess client perceptions of touch in MDMA-AT, addressing a critical gap in the current research landscape. Results: The main outcome of this research is the creation of TOMI, a tool aimed at evaluating the impact of touch on clients in MDMA-AT. The review highlights the lack of empirical evidence in this area and the necessity for such a measure. Discussion: With the increasing likelihood of MDMA-AT becoming a widely used therapy, understanding how therapeutic touch affects clients is imperative. This article emphasizes the need for evidence-based and ethical guidelines for the use of touch in MDMA-AT. The development of TOMI is a step towards achieving this, providing a means for researchers and program evaluators to assess the implications of touch in MDMA-AT and psychedelic-assisted therapy more generally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.